Table 3

Multivariate analysis of poor psychological outcomes: survivor and survivor subgroups compared with siblings

AnxietyDepressionSomatic distressGlobal distress
OR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
Siblings1.001.001.001.00
Survivors1.12 (0.47-2.67).801.15 (0.60-2.18).672.88 (1.44-5.76).0031.79 (0.81-3.93).15
By primary cancer diagnosis
    Aplastic anemia0.72 (0.13-3.97).700.72 (0.21-2.52).612.06 (0.62-6.80).231.34 (0.35-5.16).67
    Chronic myeloid leukemia1.01 (0.36-2.79).991.34 (0.64-2.81).433.53 (1.65-7.55).0012.19 (0.92-5.24).08
    Acute myeloid leukemia1.14 (0.41-3.16).811.47 (0.70-3.06).313.25 (1.50-7.01).0031.88 (0.77-4.57).16
    Hodgkin lymphoma0.20 (0.02-1.75).140.21 (0.04-1.00).052.18 (0.82-5.81).120.53 (0.13-2.23).39
    Non-Hodgkin lymphoma1.64 (0.59-4.55).341.14 (0.51-2.58).752.77 (1.24-6.21).012.43 (0.97-6.08).06
    Acute lymphoblastic leukemia1.32 (0.40-4.37).651.52 (0.64-3.59).342.35 (0.91-6.08).081.53 (0.53-4.43).43
    Multiple myeloma1.06 (0.22-5.09).950.60 (0.14-2.53).494.45 (1.53-12.92).011.26 (0.31-5.19).75
    Others1.45 (0.28-7.53).660.96 (0.25-3.76).960.47 (0.06-3.90).491.16 (0.22-6.01).86
By stem cell donor
    Autologous HCT1.01 (0.39-2.58).991.02 (0.51-2.06).952.60 (1.25-5.38).011.53 (0.66-3.55).32
    Allogeneic, sibling donor1.15 (0.45-2.92).781.34 (0.68-2.65).402.88 (1.38-6.02).001.96 (0.85-4.49).11
    Allogeneic, unrelated donor1.54 (0.48-4.90).470.91 (0.35-2.36).854.32 (1.84-10.18).0012.28 (0.83-6.21).11
By risk of relapse at HCT
    Standard risk0.89 (0.32-2.44).821.15 (0.55-2.39).712.67 (1.22-5.84).011.75 (0.73-4.18).21
    High risk1.84 (0.64-5.29).261.17 (0.51-2.68).724.18 (1.79-9.74).0011.99 (0.76-5.24).16
By transplant regimens
    Chemotherapy alone0.70 (0.16-3.11).640.75 (0.26-2.20).602.42 (0.87-6.79).090.90 (0.25-3.22).87
    Total body irradiation–based1.24 (0.47-3.24).661.23 (0.60-2.51).573.15 (1.46-6.76).0032.00 (0.85-4.70).11
By cGVHD status (among allogeneic HCT survivors only)
    No1.17 (0.41-3.33).770.89 (0.40-1.99).782.32 (1.01-5.33).051.32 (0.51-3.41).56
    Active cGVHD1.96 (0.66-5.79).221.40 (0.60-3.25).445.14 (2.21-11.89)< .0013.04 (1.17-7.88).02
    Resolved cGVHD0.56 (0.16-1.99).371.34 (0.60-3.00).472.49 (1.04-5.97).041.61 (0.61-4.28).34
By exposure to immunosuppressants (among allogeneic HCT survivors only)
    Use of any immunosuppression1.23 (0.47-3.19).681.20 (0.59-2.44).613.00 (1.40-6.43).0051.90 (0.81-4.44).14
    Methotrexate1.22 (0.46-0.00).691.06 (0.51-2.21).873.15 (1.46-6.79).081.75 (0.73-4.19).21
    Cyclosporine1.22 (0.46-3.26).691.46 (0.71-2.99).313.32 (1.54-7.15).0032.04 (0.86-4.85).11
    Prednisone1.63 (0.62-4.33).331.53 (0.74-3.18).253.76 (1.72-8.21).1062.46 (1.02-5.91).04
  • OR indicates odds ratio; CI, confidence interval; HCT, hematopoietic cell transplantation; and cGVHD, chronic GVHD.